The prevalence of antibodies to adenovirus serotype 5 in an adult indian population and implications for adenovirus vector vaccines

Journal of Medical Virology

Volumn 82, Issue 3, 2010, Pages 407-414

  Pilankatta, Rajendra ^a,b   Chawla, Tanu ^a,c   Khanna, Navin ^a   Swaminathan, Sathyamangalam ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Adenoviral vaccine; Adenovirus; CAR; Fc receptor; Prior adenovirus immunity

Indexed keywords

ADENOVIRUS VECTOR; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; FC RECEPTOR; GREEN FLUORESCENT PROTEIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS VACCINE;

ADENOVIRUS 5; ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CELL LINE; CELL STRAIN U937; CONTROLLED STUDY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; INDIA; MALE; NORMAL HUMAN; PROTEIN EXPRESSION; REPORTER GENE; VIRAL GENE DELIVERY SYSTEM; VIRUS ENTRY;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ADULT; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; BLOOD DONORS; CELL LINE; FEMALE; GENETIC VECTORS; HUMANS; INDIA; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; SEROEPIDEMIOLOGIC STUDIES; VIRUS INTERNALIZATION;

ADENOVIRIDAE; COXSACKIEVIRUS; HUMAN ADENOVIRUS;

EID: 75449119950     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21721     Document Type: Article

References (53)

1. Abbink P, Lemckert AAC, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, O'Brien KL, Carville A, Mansfield KG, Goudsmit J, Havenga MJE, Barouch DH. 2007. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81:4654-4663.
2. Aste-Amézaga M, Bett AJ, Wang F, Casimiro DR, Antonello JM, Patel DK, Dell EC, Franlin LL, Dougherty NM, Bennett PS, Perry HC, Davies ME, Shiver JW, Keller PM, Yeager MD. 2004. Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: Application in epidemiologic studies and in the design of adenovector vaccines. Hum Gene Ther 15:293-304.
3. Bangari DS, Mittal SK. 2006. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24:849-862.
4. Barouch DH. 2006. Rational design of gene-based vaccines. J Pathol 208:283-289.
5. Barouch DH, Nabel GJ. 2005. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16:149-156.
6. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL, Goudsmit J. 2004. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172:6290-6297.
7. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. 1997. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-1323.
8. Berk AJ. 2007. Adenoviridae: The viruses and their replication. In: Knipe DM, Howley PM, editors-in-chief. Fields virology. 5th edition. Philadelphia, PA: Lippincott Williams & Wilkins. pp 2355-2394.
9. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, Dubey S, Zhu DM, Nawrocki D, Mach H, Troutman R, Isopi L, Williams D, Hurni W, Xu Z, Smith JG, Wang S, Liu X, Guan L, Long R, Trigona W, Heidecker GJ, Perry HC, Persaud N, Toner TJ, Su Q, Liang X, Youil R, Chastain M, Bett AJ, Volkin DB, Emini EA, Shiver JW. 2003. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77:6305-6313.
10. Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Gu L, Martin JE, Novik L, Chakrabarti BK, Butman BT, Gall JGD, King CR, Andrews CA, Sheets R, Gomez PL, Mascola JR, Nabel GJ, Graham BS, The Vaccine Research Center 006 Study Team. 2006. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194:1638-1649.
11. Chawla T, Khanna N, Swaminathan S. 2008. Adenovirus-vectored vaccines. Expert Opin Ther Patents 18:293-307.
12. Chen Y, Yu DC, Charlton D, Henderson DR. 2000. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for humangene therapy. Hum Gen Ther 11:1553-1567.
13. Cohen P. 2006. Immunity's yin and yang. IAVI Rep 10:1-5.
14. Ebbinghaus C, Al-Jaibaji A, Operschall E, Schöffel A, Peter I, Greber UF, Hemmi S. 2001. Functional and selective targeting of adenovirus to high-affinity Fcg receptor I-positive cells by using a bispecific hybrid adapter. J Virol 75:480-489.
15. Foxwell B, Browne K, Bondeson J, Clarke C, De Martin R, Brennan F, Feldmann M. 1998. Efficient adenoviral infection with IκBα reveals that macrophage tumor necrosis factor a production in rheumatoid arthritis is NF-κB dependent. Proc Natl Acad Sci USA 95:8211-8215.
16. Gahéry-Ségard H, Farace F, Godfrin D, Gaston J, Lengagne R, Tursz T, Boulanger P, Guillet JG. 1998. Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol 72:2388-2397.
17. He TC, Zhou S, Da Costa LT, Yu J, Kinzler KW, Vogelstein B. 1998. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95:2509-2514.
18. Hitt MM, Addison CL, Graham FL. 1997. Human adenovirus vectors for gene transfer into mammalian cells. Adv Pharmacol 40:137-206.
19. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I, Bright RA, Katz JM, Mittal SK, Sambhara S. 2006. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367:475-481.
20. Holterman L, Vogels R, van der Vlugt R, Sieuwerts M, Grimbergen J, Kaspers J, Geelen E, van der Helm E, Lemckert A, Gillissen G, Verhaagh S, Custers J, Zuijdgeest D, Berkhout B, Bakker M, Quax P, Goudsmit J, Havenga M. 2004. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: Low seroprevalence and non-cross-reactivity with Ad5. J Virol 78:13207-13215.
21. Hong SS, Habib NA, Franqueville L, Jensen S, Boulanger PA. 2003. Identification of adenovirus (Ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative Ad (Addl1520) for treatment of liver tumors. J Virol 77:10366-10375.
22. + T cells. Nat Med 8:876-878.
23. Jaiswal S, Khanna N, Swaminathan S. 2003. Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2. J Virol 77:12907-12913.
24. Khanam S, Khanna N, Swaminathan S. 2006. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. Vaccine 24:6513-6525.
25. Khanam S, Rajendra P, Khanna N, Swaminathan S. 2007. An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes. BMC Biotechnol 7:10.
26. Khanam S, Rajendra P, Khanna N, Swaminathan S. 2009. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 27:6011-6021.
27. Kim JS, Lee SH, Cho YS, Kim YH, Lee JH. 2001. Ectopic expression of the coxsackievirus and adenovirus receptor increases susceptibility to adenoviral infection in the human cervical cancer cell line SiHa. Biochem Biophys Res Commun 288:240-244.
28. Kitchen LW, Vaughn DW. 2007. Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases. Vaccine 25:7017-7030.
29. Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, Helmus N, Vogels R, Bakker M, Berkhout B, Havenga M, Goudsmit J. 2004. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18:1213-1216.
30. Leopold PL, Wendland RL, Vincent T, Crystal RG. 2006. Neutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathway. J Virol 80:10237-10247.
31. Looney RJ, Abraham GN, Anderson CL. 1986. Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol 136:1641-1647.
32. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, Robbins PD, Gambotto A. 2004. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 11:351-357.
33. O'Brien KL, Liu J, King SL, Sun YH, Schmitz JE, Lifton MA, Hutnick NA, Betts MR, Dubey SA, Goudsmit J, Shiver JW, Robertson MN, Casimiro DR, Barouch DH. 2009. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 15:873-875.
34. Perreau M, Pantaleo G, Kremer EJ. 2008. Activation of dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 205:2717-2725.
35. Piedra PA, Poveda GA, Ramsey B, McCoy K, Hiatt PW. 1998. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: Implications for gene therapy with adenovirus vectors. Pediatrics 101:1013-1019.
36. Ravetch JV, Bolland S. 2001. IgG Fc receptors. Annu Rev Immunol 19:275-290.
37. Raviprakash K, Wang D, Ewing D, Holman DH, Block K, Woraratanadharm J, Chen L, Hayes C, Dong JY, Porter K. 2008. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol 82:6927-6934.
38. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am J Hyg 27:493-497.
39. Russell KL, Hawksworth AW, Ryan MAK, Strickler J, Irvine M, Hansen CJ, Gray GC, Gaydos JC. 2006. Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004. Vaccine 24:2835-2842.
40. Schulick AH, Vassalli G, Dunn PF, Dong G, Rade JJ, Zamarron C, Dichek DA. 1997. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest 99:209-219.
41. Segerman A, Mei YF, Wadell G. 2000. Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines. J Virol 74:1457-1467.
42. Shiver JW, Emini EA. 2004. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55:355-372.
43. Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, Vogels R, Goudsmit J, Havenga MJE, Kostense S. 2003. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 41:5046-5052.
44. Sumida SM, Truitt DM, Lemckert AAC, Vogels R, Custers JHHV, Addo MM, Lockman S, Peter T, Peyerl FW, Kishko MG, Jackson SS, Gorgone DA, Lifton MA, Essex M, Walker BD, Goudsmit J, Havenga MJE, Barouch DH. 2005. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174:7179-7185.
45. Sundstrom C, Nilsson K. 1976. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 17:565-577.
46. Thorner AR, Vogels R, Kaspers J, Weverling GJ, Holterman L, Lemckert AAC, Dilraj A, McNally LM, Jeena PM, Jepsen S, Abbink P, Nanda A, Swanson PE, Bates AT, O'Brien KL, Havenga MJE, Goudsmit J, Barouch DH. 2006. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microb 44:3871-3873.
47. Tomko RP, Xu R, Philipson L. 1997. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 94:3352-3356.
48. VanKampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, Marks D, Elmets CA, Tang DC. 2005. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23:1029-1036.
49. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Béthune MP, Kostense S, Penders G, Helmus N, Koudstaal W, Cecchini M, Wetterwald A, Sprangers M, Lemckert A, Ophorst O, Koel B, vanMeerendonk M, Quax P, Panitti L, Grimbergen J, Bout A, Goudsmit J, Havenga M. 2003. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77:8263-8271.
50. Wold WSM, Horwitz MS. 2007. Adenoviruses. In: Knipe DM, Howley PM, editors-in-chief. Fields virology. 5th edition. Philadelphia, PA: Lippincott Williams & Wilkins. pp. 2395-2436.
51. Xiang ZQ, Yang Y, Wilson JM, Ertl HCJ. 1996. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219:220-227.
52. Xiang Z, Gao G, Reyes-Sandoval A, Cohen CJ, Li Y, Bergelson JM, Wilson JM, Ertl HCJ. 2002. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 76:2667-2675.
53. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. 2003. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 77:799-803.